- Home
- MDCX
as 06-20-2025 3:38pm EST
Stocks
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
| Founded: | 2008 | Country: | Canada |
| Employees: | N/A | City: | W. CONSHOHOCKEN |
| Market Cap: | 44.0M | IPO Year: | N/A |
| Target Price: | $23.50 | AVG Volume (30 days): | 423.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $1.80 - $8.94 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Medicus Pharma Ltd. Common Stock News
MDCX Breaking Stock News: Dive into MDCX Ticker-Specific Updates for Smart Investing
Newsfile
9 days ago
Medicus Pharma Ltd. to Present at 2025 Bio International Convention
Newsfile
12 days ago
Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses
Newsfile
19 days ago
Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering
GlobeNewswire
22 days ago
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
Newsfile
22 days ago
Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering
Newsfile
a month ago
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
Newsfile
2 months ago
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
Newsfile
2 months ago
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
Compare MDCX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MDCX Medicus Pharma Ltd. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.